“Gastrointestinal Therapeutics market set to grow to $68bn by 2028” says new Visiongain report

04 October 2019
Pharma

Visiongain has published a new pharma report Top 50 Gastrointestinal Therapeutic Companies 2020: GlaxoSmithKline, Abbott, Allergan, Eli Lilly, Evoke Pharma, Other Companies.

The gastrointestinal (GI) therapeutics industry is on the rise; growing to reach $68,237.0m by 2028. This growth stems from rising prevalence of GI disorders. Moreover, the increase in R&D has been a priority of the big pharma companies to infuse the drug pipelines with a new set of candidates with a high potential of reaching the clinical stage. However, the pricing pressure due to rising competition has hampered the market growth. On the contrary, the expiry of high-profile patents, which will carve the path for the launch of generic drugs in the market can provide growth opportunities to the other players in the market.

This report profiled the selected companies: Abbott, AbbVie, Alexion Pharmaceuticals, Allergan, ANI Pharmaceuticals, Inc., AstraZeneca, Bayer AG, Biogen, Eisai Co., Ltd., Eli Lilly, Evoke Pharma, GlaxoSmithKline and other companies.

The lead analyst commented that "Emerging economies of Asia-Pacific and LAMEA possess high potential for gastrointestinal drugs. The rise in purchasing power in these economies is expected to augment the market growth. Rise in awareness regarding GI diseases such as, ulcerative colitis, IBD and cancer and the use of novel drugs the treatment of these diseases in the developing regions, have resulted in regulatory authorities in these regions to take key decisions to improve the legislations of gastrointestinal drugs."

Notes for Editors
f you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 207 336 6100.

About Visiongain
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

A Breakdown of Biosimilar Market Size, Benefits & Challenges

Biosimilars were developed to give consumers more affordable options when it comes to purchasing medicine. In the simplest of terms, they’re a copy of an already existing biological medicine in the marketplace that has been thoroughly tested and deemed safe for use. As the need for more access to healthcare and affordable medicine continues to increase, so has the global …

08 October 2019

Read

“Global Surgical Sutures market set to grow to $6.4bn by 2024” says new Visiongain report

The global market for surgical sutures is witnessing steady growth primarily due to the increasing number of surgical procedures conducted, globally.

08 October 2019

Read

“Gastrointestinal Therapeutics market set to grow to $68bn by 2028” says new Visiongain report

Emerging economies of Asia-Pacific and LAMEA possess high potential for gastrointestinal drugs.

04 October 2019

Read

“Advanced Wound Care market set to grow to $13.8bn by 2024” says Visiongain report

Being the largest and fastest growing segment of the wound care market, the Advanced wound care market will witness healthy growth during the forecast period.

03 October 2019

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever